image: Infection biology studies up to safety level three are possible at the German Primate Center.
Credit: Thomas Steuer
Pandemics threaten both human health and the global economy. Vaccines are an essential part of the fight against pandemics, but they are only available months after the outbreak. Broad-spectrum drugs, on the other hand, could limit the spread of a pathogen at an early stage and save many lives. While broad-spectrum drugs are available to treat bacterial infections, there are no comparable drugs for viruses. The "Vigilant" research network aims to close this dangerous gap. The network is coordinated by the German Primate Centre - Leibniz Institute for Primate Research and funded by the EU with around €7.5 million over four years.
Viral pandemics such as COVID-19 pose a serious threat to global health. The development and approval of vaccines and antiviral drugs can take many months. In addition, antivirals are often only effective against a narrow spectrum of viruses. To better combat future viral pandemics, it is essential to have drugs with broad antiviral activity that can be used immediately, without prior knowledge of the pathogen. Such drugs could, when used as prophylaxis, reduce the spread of a pathogen and possibly prevent a local outbreak from developing into a global pandemic. At the same time, they could be used as a therapy to help infected patients avoid severe disease, thereby reducing the burden on healthcare systems.
The "Vigilant" research network, funded by the EU's Horizon Europe program, aims to develop compounds with broad antiviral activity. "Vigilant" brings together the expertise of researchers in biochemistry, medicinal chemistry, molecular and cell biology and virology. The network is coordinated by the German Primate Center and is funded by the EU with 1.6 million euros.
Research will focus on viral envelope proteins. These proteins serve as "keys" for viruses to enter host cells. If it is possible to block the transport and activation of these viral envelope proteins in infected cells, the replication of viruses in the body would be stopped. As different viruses use the same cellular factors for transport and activation of their envelope proteins, the inhibitors developed could exert a broad antiviral activity. This will be investigated in cell culture and in animal experiments with mice, ferrets and monkeys.
“Vigilant pursues two innovative approaches to antiviral therapy: inhibiting the transport of viral envelope proteins into the endoplasmic reticulum of infected cells and blocking the activation of envelope proteins by cellular proteases,” explains Stefan Pöhlmann, coordinator of the Vigilant consortium and head of the Infection Biology Unit at the German Primate Center. “Vigilant will produce new compounds that will significantly improve our preparedness for future pandemics," says Pöhlmann.
Contact and notes for editors
Prof. Dr. Stefan Pöhlmann
Phone: +49 (0)551 3851-150
Email: spoehlmann@dpz.eu
Dr. Susanne Diederich (Communication)
Phone: +49 (0) 551 3851-359
Email: sdiederich@dpz.eu
Printable pictures are available here: https://medien.dpz.eu/pinaccess/showpin.do?pinCode=YzCWuWMeO1jM
You will also find the press release on our website. Please send us a reference copy or link in case of publication.
The German Primate Center GmbH (DPZ) – Leibniz Institute for Primate Research conducts biological and biomedical research on and with primates in the fields of infection research, neuroscience and primate biology. The DPZ also maintains four field stations in the tropics and is a reference and service center for all aspects of primate research. The DPZ is one of the 96 research and infrastructure facilities of the Leibniz Association.